05
September 2018
iX Biopharma Ltd is pleased to announce the success of its Phase 2 multi-dose clinical study (“KET010”) for Wafermine, its sublingual ketamine wafer for pain management...
Read On27
August 2018
iX Biopharma capped off its financial year ended 30 June 2018 by achieving several major milestones in its pharmaceutical and nutraceutical businesses...
Read OnSublingual wafer administration offers the convenience of use over oral delivery, circumventing the drug breakdown in liver or gastrointestinal tract. The technology also provides rapid absorption, achieving maximum desirable therapeutic effect in a non-invasive manner.
Read OnThe Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine
Oxford Journal on Pain Medicine, 2017The absolute bioavailability of racemic ketamine from a novel sublingual formulation
British Journal of Clinical Pharmacology, 2013A Phase I Pharmacokinetic and Bioavailability Study of a Sublingual Fentanyl Wafer in Healthy Volunteers
Anesthesia and Analgesia, 20121 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com